Deutsch Website, wo Sie Qualität und günstige https://medikamenterezeptfrei2014.com/ Viagra Lieferung weltweit erwerben.

Ein wenig Kopfschmerzen, aber schnell verging der Schmerz. Gefühle, die ich erlebte ein unvergessliches kamagra kaufen Ehrlich gesagt nicht wirklich glauben, in der Kraft Viagra. Setzte nach der Anleitung. Das Ergebnis ist natürlich, sich selbst rechtfertigte.

Microsoft word - anthonygrassocv 2008.doc

Anthony R. Grasso, Jr., M.D.

EDUCATION

University of Connecticut School of Medicine
Farmington, CT
Medical Doctor
College of the Holy Cross

POSTGRADUATE EDUCATION
National Rehabilitation Hospital

Washington, DC
Residency, Physical Medicine & Rehabilitation
Georgia Baptist Medical Center
Atlanta, GA
Internship, Transitional Year
PROFESSIONAL EXPERIENCE

CLINICAL RESEARCH EXPERIENCE
Protocol No. 3200A3-2201-US: A multicenter, randomized, double-blind, placebo-controlled,
parallel-group study of ORAL MOA-728 for the treatment of opioid-induced bowel dysfunction in
subjects with chronic non-malignant pain.12/2007
Protocol TD-07-14: The efficacy and safety of TDS-943 in the treatment of osteoarthritis of the
knee: Pivotal Study II. 10/2007
KF5503/18 (Grunenthal); R331333-PAI-3010 (J&J PRD): Open-Label Extension, Single-Arm,
Flexible-Dosing, Phase III Trial with CG5503 Extended-Release (ER) in
Subjects with Moderate to Severe Chronic Pain. 11/2007
Protocol No. BUP3025: A Multi-center, Randomized, Double-blind, Placebo-controlled Study with
an Open-label Run-in Assess the Efficacy, Tolerability, and Safety of BTDS 10 or BTDS 20
Compared to Placebo in Opioid-naïve Subjects with Moderate to Severe, Chronic Pain due to
Osteoarthritis of the Knee. 10/2007
SPI/0211OBD-0631: A multi-center, Randomized, Placebo-Controlled, Double-Blinded Study of the
Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction. 10/2007

SPI/0211OBD-06S1: A multicenter, open-labled study of the long-term Safety and Efficacy of
Lubiprostone in Patients with Opioid-induced Bowel dysfunction. 2007
Protocol No. 3200K1-3356-WW: A Multi-center, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation
in Subjects with Chronic Non-Malignant Pain. 2007
Penwest-Protocol NAL-20: Randomized, double blind placebo controlled dose escalation study of
the analgesic efficacy of Nalbuphine-ER in patients with Chronic Pain Secondary to Osteoarthritis of
the Knee/Hip. 2007

HTF919N2302, entitled “An open label 52-week study to evaluate the safety and efficacy of
tegaserod (6 mg b.i.d. and 12 mg o.d.) given orally for the treatment of opioid-induced constipation
(OIC) in patients with chronic non-cancer pain” Novartis) 2007

ALO-KNT-302. A Long-Term, Open-Label, Safety Study of Kadian NT (Morphine Sulfate Plus
Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Chronic Moderate to
Severe Nonmalignant Pain. (Alpharma / INC Research) 2006
ALO-KNT-301. A Multicenter, Randomized, Placebo-Controlled, Phase 3 Efficacy Study of Kadian
NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee. (Alpharma / INC
Research) 2006
A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial with
Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release
(ER) in Subjects with Moderate to Severe Chronic Low Back Pain. Protocol KF5503/23(Grünenthal)
R331333-PAI-3011 (J&JPRD): Johnson & Johnson 2007
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-
728 For the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Non-
Malignant Pain Wyeth Pharmaceuticals (3200A3-200-WW). Phase II. 2006
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy,
Tolerability and Safety of XXXX topical patch in the Treatment of Pain Associated with Tendonitis
or Bursitis of the Shoulder, Elbow or Knee. EN3269-302. 2006
CCOX189A2367 A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-
controlled, parallel group trial of XXXX (COX189) 100 mg o.d. in patients with primary hip
osteoarthritis using celecoxib (200 mg o.d.) as a positive control. (Novartis – PPD Development)
2005 - 2006

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the
Efficacy and Safety of XXXX 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced
Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain. SB-
767905/012 2005
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-
Term Safety of XXXX 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel
Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain. SB-767905/014. 2005

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the
Safety and Efficacy of HKT-500 in Subjects with Pain from Moderate Lateral Epicondylitis. HKT-
500-US05. 2005
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the
Safety and Efficacy of HKT-500 in Subjects with low back pain. HKT-500-US04. 2005

A Phase III Pivotal, Multi-center, Double-Blind, Randomized, Placebo-Controlled Monotherapy
Study of (Study Drug) for Treatment of Fibromyaligia. Forest Laboratories / Scirex. (MLN-MD-02)
2004.
A Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase Ilb Study to Evaluate the
Efficacy and Safety of Multiple Alvimopan Dosage Regimes for the Treatment of Opioid-Induced
Bowel Dysfunction in Subjects with Chronic Pain of Non-Malignant Origin. GlaxoSmithKline. (SB-
767905/011). 2004 - 2005

A Multicenter, Randomized, Double-Blind, Active Comparator Study to Determine the Efficacy and
Safety of BTDS 20 and OxyIR® versus BTDS 5 in Subjects with Moderate to Severe Osteoarthritis
(OA) Pain. Purdue Pharma. (BUP3019) 2004 -2005
Flexeril® Community Based Study. Kendle / McNeil. 3/2004 (Protocol 19-401).
A Randomized, Parallel-Design, Multicenter Study To Evaluate The Efficacy of Avinza® vs
Oxycontin® For The Treatment of Chronic Low Back Pain. Scirex / Organon (Protocol 178900)
2004

A 4 Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of SD-
6010 in Subjects with Symptomatic Osteoarthritis of the Knee. (Protocol A6171009). Pfizer.
January 2004.
A Phase III, Randomized, Double-Blind, Fixed Dose, Parallel-Group Comparison of Controlled-
Release Hydromorphone Hydrochloride (HCI) vs Placebo in Subjects with Osteoarthritis (Protocol
M03-644). Abbott / Scirex January 2004.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine
the Efficacy and Safety of the Buprenorphine Transdermal Delivery System (BTDS) in Subjects with
Moderate to Severe Osteoarthritic Pain of the Hip or Knee. Purdue Pharma. (BUP3012). 2003 -
2004
An Open-Label, Long-Term Effectiveness and Safety of Oxymorphone Extended Release Tablets
in Patients with Cancer or Neuropathic Pain. Endo Pharmaceuticals Inc.,. (EN3202-029) 2003 -
2004
Dose Escalation of Active Comparator vs. Morphine in Opioid-Responsive Chronic Pain Patients (KND035). 2001 Cardiovascular Safety of Etoricoxib and Diclofenac in Patients With OsteoArthritis and Rheumatoid Arthritis 2002-2003
MK-0663 Protocol 072-00 (EDGE II) A Randomized, Double-Blind, Multicenter Study to Evaluate
the Tolerability and Effectiveness of Etoricoxib 90mg Q.D. vs Diclofenac Sodium 75mg B.I.D. in
Patients with Rheumatoid Arthritis 2003
A Usual Care, Multicenter, Open-Label, Randomized, 4-Month Parallel-Group Trial to Compare the
Impact of Therapy with OxyContin ® (Controlled-Release Oxycodone) vs. Usual Care (Percocet ®)
on Health Outcomes and Resource Utilization in Subjects with Moderate to Severe Osteoarthritis
Pain of the Hip or Knee; 2002
Phase II Study on Analgesic Efficacy, Safety, and Tolerability of AZD3582: A 6 Week, Double Blind,
Randomized, Placebo-Controlled, Dose-Finding, Multicentre Study Comparing AZD3582 with
Rofecoxib (Vioxx ) in Subjects With Osteoarthritis of the Hip or Knee (ZEN010); 2002
A Multicenter, Randomized, Double-Blind, Active- and Placebo-Controlled. Phase II Dose
Escalation, Efficacy and Safety Study of Oxycodone HCL and Low-Dose Naltrexone-HCL in
Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee (SCX038);
2002
A Double-Blind, Placebo Controlled, Parallel-Group, 12 Week Trial to Assess the Efficacy and
Safety of XXX in Patients with Chronic Low Back Pain; 2000
PRESENTATIONS
“Management of Fibromyalgia and Myofascial Pain Syndromes” Arthritis Foundation
“Critical Illness Polyneuropathy: Long-term Functional Outcomes”, Grasso, A., Aseff, J.,
Gerber,L., National Rehabilitation Hospital Grand Rounds, June 1997.
“Whiplash Syndrome: Diagnosis and Management,” National Rehabilitation Hospital, February
1997.
“Elevated Erythrocyte Sedimentation Rate in a Paraplegic Patient who Developed a Deep Venous
Thrombosis,”
Rasul, A., Houston, J., Grasso, A., poster presentation, November 1995 AAPM&R
Meeting.
“Management of Scoliosis in Duchenne Muscular Dystrophy,” presented at Children’s
National Medical Center, Department of Physical Medicine and Rehabilitation, September 1995.
“Medical Complications in the Therapy Gym,” Conroy, B., Grasso, A., National Rehabilitation
Hospital Physical & Occupational Therapy Grand Rounds, November 1994.
“The post-occlusive fibrinolytic response in exercise trained and untrained quadriplegics,”
Arnold, P., Nash, M., Grasso, A., Newington Children’s Hospital, 1993
Arnold, P., Farrell, W., McVey, P., Deurloo, T., Grasso, A., “Functional Electric Stimulation: It’s
Efficacy and Safety in Improving Pulmonary Function and Musculoskeletal Fitness,”
Archives of
Physical Medicine and Rehabilitation, July 1992.
Grasso, A., Aller, S., Landsberg, J., Epstein, F., Forrest, J., Silva, P., “Neuropeptide Y Inhibits Chloride Secretion of the Rectal Gland of Squalus acanthias,” The Bulletin, Mount Desert Island Biological Laboratory, vol. 29, 1990.
LICENSES & CERTIFICATIONS
American Board of Physical Medicine and Rehabilitation, certified May 1998
Diplomate, National Board of Medical Examiners, June 1994
Advanced Cardiac Life Support
PROFESSIONAL MEMBERSHIPS & ACTIVITIES
Physiatric Association of Spine, Sports and Occupational Rehabilitation
American Academy of Physical Medicine and Rehabilitation
Staff Physician, several local hospitals
Speaker, Arthritis Foundation
Public Health Education and Wellness Examinations
Local High School Athletics Volunteer Physician




Source: http://www.lowbackpain.com/pdfs/AnthonyGrassoCV%202008.pdf

kleintierpraxis-steinbergkirche.de

Newsletter Juni 2012 Mein Tier trinkt viel Übermäßiges Trinken fällt dem Tierbesitzer meist nicht sofort auf, insbesondere, wenn mehrere Tiere im Haushalt leben. Auffällig ist häufig das extrem nasse Katzenklo oder auch der Hund, der unsauber wird oder nachts raus muss. Als grober Richtwert des normalen Wasserbedarfs pro Tag können bei einem Hund mit 10 Kilogramm Körper

þÿ

Material Safety Data Sheet 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Name Catalog No. Recommended Use Recommended Use antibiotic/antimycotic for cell culture, blocks the binding of tRNA to the 30S subunit Synonyms ACHROMYCIN HYDROCHLORIDE * ALA TET * AMYCIN, HYDROCHLORIDE*ARTOMYCIN * BRISTACYCLINE * CANCYCLINE-250 * CEFRACYCLINETABLETS

Copyright © 2010-2014 Health Drug Pdf